Display options
Cite
Aoto K, Ito K, Aoki S. Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts. Oncotarget. 2018;9(75):34090-34102doi: 10.18632/oncotarget.26124.
Aoto, K., Ito, K., & Aoki, S. (2018). Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts. Oncotarget, 9(75), 34090-34102. https://doi.org/10.18632/oncotarget.26124
Aoto, Kaori, et al. "Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts." Oncotarget vol. 9,75 (2018): 34090-34102. doi: https://doi.org/10.18632/oncotarget.26124
Aoto K, Ito K, Aoki S. Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts. Oncotarget. 2018 Sep 25;9(75):34090-34102. doi: 10.18632/oncotarget.26124. eCollection 2018 Sep 25. PMID: 30344924; PMCID: PMC6183337.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Sep 25;9(75):34090-34102. doi: 10.18632/oncotarget.26124. eCollection 2018 Sep 25.

Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts.

Oncotarget

Kaori Aoto, Kousei Ito, Shigeki Aoki

Affiliations

  1. Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba-city, Chiba 260-8675, Japan.

PMID: 30344924 PMCID: PMC6183337 DOI: 10.18632/oncotarget.26124

Abstract

Cancer-associated fibroblasts (CAFs) have recently gained attention as potent targets in cancer therapy because they are a crucial component of the tumor microenvironment and promote the growth and invasion of cancer cells. CAFs differentiate from fibroblasts, mesenchymal stem cells (MSCs), epithelial cells, and other cell types in response to transforming growth factor β (TGFβ) stimulation. The drugs tranilast, imatinib, and pirfenidone reportedly inhibit the differentiation of such cells into CAFs; however, it is unclear how they regulate TGFβ signaling. Here, we differentiated MSCs into CAFs

Keywords: PDGFRβ; TGFβ signaling; cancer-associated fibroblast; mesenchymal stem cell

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.

References

  1. Am J Cancer Res. 2011;1(4):482-97 - PubMed
  2. FEBS Lett. 2012 Jul 4;586(14):1871-84 - PubMed
  3. Biochem Biophys Res Commun. 2003 Oct 31;310(4):1124-32 - PubMed
  4. Cell. 2006 Mar 10;124(5):897-900 - PubMed
  5. Nat Cell Biol. 2003 May;5(5):410-21 - PubMed
  6. Ther Adv Respir Dis. 2012 Apr;6(2):107-14 - PubMed
  7. Cytokine Growth Factor Rev. 2004 Aug;15(4):205-13 - PubMed
  8. Science. 2002 May 10;296(5570):1046-9 - PubMed
  9. Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 - PubMed
  10. Cancer Lett. 2008 Aug 8;266(2):263-74 - PubMed
  11. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  12. Jpn J Pharmacol. 1988 Jan;46(1):43-51 - PubMed
  13. Nat Rev Cancer. 2006 May;6(5):392-401 - PubMed
  14. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1279-85 - PubMed
  15. Exp Cell Res. 2001 Mar 10;264(1):169-84 - PubMed
  16. Am J Physiol Renal Physiol. 2008 Jul;295(1):F215-25 - PubMed
  17. Cancer Res. 2015 Mar 1;75(5):813-23 - PubMed
  18. Int J Cancer. 2011 Apr 15;128(8):1783-92 - PubMed
  19. Cancer Lett. 2007 Jun 8;250(2):329-38 - PubMed
  20. Arch Biochem Biophys. 2002 Feb 15;398(2):284-90 - PubMed
  21. Haematologica. 2003 Apr;88(4):408-15 - PubMed
  22. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  23. Cell Res. 2009 Jan;19(1):128-39 - PubMed
  24. Scand J Immunol. 2014 Dec;80(6):408-16 - PubMed
  25. Neoplasia. 2013 Feb;15(2):204-17 - PubMed
  26. Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86 - PubMed
  27. Adv Cancer Res. 2007;97:247-74 - PubMed
  28. Int J Dev Biol. 2004;48(5-6):509-17 - PubMed
  29. Cancer Res. 2006 Dec 1;66(23):11314-22 - PubMed
  30. Cancer Cell. 2004 Oct;6(4):333-45 - PubMed
  31. Lancet. 2013 Jun 1;381(9881):1943-55 - PubMed
  32. J Biol Chem. 2013 Nov 15;288(46):33483-93 - PubMed
  33. Int J Cancer. 2001 Mar 15;91(6):757-62 - PubMed
  34. Hepatology. 1995 Jan;21(1):232-9 - PubMed
  35. Am J Respir Cell Mol Biol. 1995 Oct;13(4):496-505 - PubMed
  36. Am J Pathol. 2009 Jul;175(1):334-41 - PubMed
  37. Eur J Pharm Sci. 2014 Jul 16;58:13-9 - PubMed
  38. Free Radic Biol Med. 2012 Mar 15;52(6):983-92 - PubMed
  39. Cell Physiol Biochem. 2014;34(2):368-82 - PubMed
  40. J Allergy Clin Immunol. 1976 May;57(5):396-407 - PubMed
  41. J Biol Chem. 2008 Jul 18;283(29):19948-56 - PubMed
  42. Nat Rev Mol Cell Biol. 2005 Feb;6(2):112-26 - PubMed
  43. Science. 1999 Apr 2;284(5411):143-7 - PubMed
  44. J Clin Invest. 2003 Oct;112(8):1142-51 - PubMed
  45. Genes Dev. 2016 May 1;30(9):1002-19 - PubMed
  46. Nat Med. 1996 May;2(5):561-6 - PubMed
  47. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed

Publication Types